Innovative immunosuppression in kidney transplantation:A challenge for unmet needs
作者机构：Department of Renal TransplantationCareggi University HospitalFlorence 50139Italy Division of NephrologySanta Maria Annunziata HospitalFlorence 50012Italy
出 版 物：《World Journal of Transplantation》 (世界移植杂志)
年 卷 期：2022年第12卷第3期
页 面：27-41页
学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学]
主 题：New drugs Unmet needs in kidney transplantation Delayed graft function Long-term outcomes Kidney inflammation Anti-human leukocyte antigen antibodies
摘 要：Due to the optimal results obtained in kidney transplantation and to the lack of interest of the industries,new innovative drugs in kidney transplantation are difficult to be *** best strategy to find the new drugs recently developed or under development is to search in the sections of kidney transplantation still not completely covered by the drugs on the *** unmet needs are the prevention of delayed graft function(DGF),the protection of the graft over the long time and the desensitization of preformed anti human leukocyte antigen antibodies and the treatment of the acute antibody-mediated *** needs are particularly relevant due to the expansion of some kind of kidney transplantation as transplantation from non-heart beating donor and in the case of antibody-incompatible *** first are particularly exposed to DGF,the latter need a safe desensitization and a safe treatments of the antibody mediated rejections that often *** caution is needed in treating these ***,they are described in very recent studies and the follow-up of their effect is of course rather ***,some of these drugs are still in an early phase of study,even if in well-conducted randomized controlled *** caution and a careful check need to be used in trials launched 2 or 3 years ***,is always necessary to verify whether the study is still going on or whether and why the study itself was abandoned.
维普期刊数据库